Our Opinion

Inventiva S.A. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company stated in the following report that they exploit animals for product testing.

“Pharmacological inhibition of RORg by small molecules has been observed to suppress Th17 cell differentiation as well as IL-17 production, block cutaneous inflammation in animal models of psoriasis and inhibit Th17 signature gene expression by cells isolated from psoriatic patient samples. RORg is therefore a validated drug target for the treatment of psoriasis, and potentially other cutaneous inflammatory disorders.” (Page 125) Read the full document

Company Description

Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration.

Company Website: https://inventivapharma.com